News

Discover how roflumilast foam transforms treatment for seborrheic dermatitis, showing effectiveness across diverse skin tones.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

New phase 2b data reveals temtokibart significantly improves atopic dermatitis symptoms in adult patients.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

When compared to transitions of care coordinators, MIH saw no additional benefit to either health status or 30-day hospital readmissions for postacute patients with HF.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.

Avapritinib shows significant long-term benefits for indolent systemic mastocytosis while maintaining a favorable safety profile.

Brogan discusses the various opportunities and challenges that have accompanied recent evolutions in inflammatory bowel disease management.

A study shows children in remission can safely consume peanuts without daily dosing, supporting remission as the primary treatment goal over desensitization.

Patients with atopic dermatitis treated with camoteskimab saw significant reductions in their mean EASI score at Week 16 compared to placebo.

In this analysis, the degree to which each dermatological condition impacts biological aging was highlighted using epigenetic clocks.

Arora discusses the results of Bristol Myers Squibb’s observational study and the implications it has for the study of obstructive HCM and cardiology at large.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Stewart reviews clinical pearls for performing rectal exams and explains common mistakes and misdiagnoses as well as how to avoid them.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.